cancers. MiR Sentinel Prostate Cancer Test powers the platform.This liquid biopsy urine test is able to detect, classify, and monitor prostate cancer using small non-coding RNAs extracted from urine exosomes. miR Scientific develops interoperable products and services to revolutionize the standards of care for urologic oncology, including prostate, bladder, and other urothelial cancers. New standards are urgently needed due to the prevalence of these cancers and their debilitating effects around the world. MiR Scientific is a wholly owned subsidiary of Impact NRS LLC, which is headquartered in New York City and operates subsidiaries in Israel, Canada, and Puerto Rico.